Specific Proteins - Medical Devices Pipeline Assessment, 2019

Published : Dec-2019

No. of Pages : 123

order by fax Inquire before Buying request discount

Table of Contents
1.1 List of Tables 5
1.2 List of Figures 8
2 Introduction 9
2.1 Specific Proteins Overview 9
3 Products under Development 10
3.1 Specific Proteins - Pipeline Products by Stage of Development 10
3.2 Specific Proteins - Pipeline Products by Territory 11
3.3 Specific Proteins - Pipeline Products by Regulatory Path 12
3.4 Specific Proteins - Pipeline Products by Estimated Approval Date 13
4 Specific Proteins - Pipeline Products under Development by Companies 14
4.1 Specific Proteins Companies - Pipeline Products by Stage of Development 14
4.2 Specific Proteins - Pipeline Products by Stage of Development 15
5 Specific Proteins Companies and Product Overview 18
5.1 Abbott Diagnostics Company Overview 18
5.1.1 Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 18
5.2 Alfa Wassermann Diagnostic Technologies, LLC Company Overview 20
5.2.1 Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 20
5.3 Amerimmune LLC Company Overview 22
5.3.1 Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 22
5.4 Analyticon Biotechnologies AG Company Overview 24
5.4.1 Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 24
5.5 Beckman Coulter Inc Company Overview 29
5.5.1 Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 29
5.6 China Medical Technologies Inc (Inactive) Company Overview 37
5.6.1 China Medical Technologies Inc (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 37
5.7 Colorado State University Company Overview 38
5.7.1 Colorado State University Pipeline Products & Ongoing Clinical Trials Overview 38
5.8 Fujirebio Diagnostics Inc Company Overview 39
5.8.1 Fujirebio Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 39
5.9 Genesis Detection Systems, Inc. Company Overview 40
5.9.1 Genesis Detection Systems, Inc. Pipeline Products & Ongoing Clinical Trials Overview 40
5.10 Genome Diagnostics Pvt. Ltd. Company Overview 41
5.10.1 Genome Diagnostics Pvt. Ltd. Pipeline Products & Ongoing Clinical Trials Overview 41
5.11 Guanine Inc Company Overview 42
5.11.1 Guanine Inc Pipeline Products & Ongoing Clinical Trials Overview 42
5.12 Hologic Inc Company Overview 43
5.12.1 Hologic Inc Pipeline Products & Ongoing Clinical Trials Overview 43
5.13 Isoformix Inc Company Overview 44
5.13.1 Isoformix Inc Pipeline Products & Ongoing Clinical Trials Overview 44
5.14 Kobe University Company Overview 45
5.14.1 Kobe University Pipeline Products & Ongoing Clinical Trials Overview 45
5.15 Ortho-Clinical Diagnostics Inc Company Overview 46
5.15.1 Ortho-Clinical Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 46
5.16 Ottawa Hospital Research Institute Company Overview 49
5.16.1 Ottawa Hospital Research Institute Pipeline Products & Ongoing Clinical Trials Overview 49
5.17 Roche Diagnostics International Ltd Company Overview 50
5.17.1 Roche Diagnostics International Ltd Pipeline Products & Ongoing Clinical Trials Overview 50
5.18 Sebia SA Company Overview 57
5.18.1 Sebia SA Pipeline Products & Ongoing Clinical Trials Overview 57
5.19 Siemens Healthcare Diagnostics Inc Company Overview 58
5.19.1 Siemens Healthcare Diagnostics Inc Pipeline Products & Ongoing Clinical Trials Overview 58
5.20 Siemens Healthineers AG Company Overview 66
5.20.1 Siemens Healthineers AG Pipeline Products & Ongoing Clinical Trials Overview 66
5.21 The Binding Site Group Ltd Company Overview 68
5.21.1 The Binding Site Group Ltd Pipeline Products & Ongoing Clinical Trials Overview 68
5.22 Umea University Company Overview 69
5.22.1 Umea University Pipeline Products & Ongoing Clinical Trials Overview 69
5.23 University of California Company Overview 70
5.23.1 University of California Pipeline Products & Ongoing Clinical Trials Overview 70
6 Specific Proteins- Recent Developments 71
6.1 Oct 30, 2019: PerkinElmer announces financial results for the third quarter of 2019 71
6.2 Oct 29, 2019: ELITechGroup announces direct sales and customer support in Canada 72
6.3 Oct 23, 2019: bioMerieux - Third-Quarter 2019 Business Review 72
6.4 Oct 22, 2019: bioMerieux - Third quarter 2019 business review 74
6.5 Oct 21, 2019: SomaLogic significantly expands key strategic collaboration with Novartis 75
6.6 Oct 16, 2019: Abbott reports third-quarter 2019 results 76
6.7 Oct 01, 2019: Opthea receives A$14.6mR&D tax incentive 78
6.8 Sep 04, 2019: bioMerieux announces First-Half 2019 Results 79
6.9 Aug 29, 2019: Siemens Healthineers announces new Canadian leadership 82
6.10 Aug 21, 2019: PerkinElmer announces leadership succession plan 83
7 Appendix 120
7.1 Methodology 120
7.2 About GlobalData 123
7.3 Contact Us 123
7.4 Disclaimer 123

List of Tables
Table 1: Specific Proteins - Pipeline Products by Stage of Development 11
Table 2: Specific Proteins - Pipeline Products by Territory 12
Table 3: Specific Proteins - Pipeline Products by Regulatory Path 13
Table 4: Specific Proteins - Pipeline Products by Estimated Approval Date 14
Table 5: Specific Proteins Companies - Pipeline Products by Stage of Development 15
Table 6: Specific Proteins - Pipeline Products by Stage of Development 17
Table 7: Abbott Diagnostics Pipeline Products & Ongoing Clinical Trials Overview 20
Table 8: Alinity c Assay - Cystatin C - Product Status 20
Table 9: Alinity c Assay - Cystatin C - Product Description 20
Table 10: Alinity c Assay - Immunoglobulin E - Product Status 21
Table 11: Alinity c Assay - Immunoglobulin E - Product Description 21
Table 12: Alfa Wassermann Diagnostic Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 22
Table 13: ACE Axcel System - Lp(a) Assay - Product Status 22
Table 14: ACE Axcel System - Lp(a) Assay - Product Description 22
Table 15: ACE Axcel System - Microalbumin Assay - Product Status 23
Table 16: ACE Axcel System - Microalbumin Assay - Product Description 23
Table 17: ACE Axcel System - Transferrin Assay - Product Status 23
Table 18: ACE Axcel System - Transferrin Assay - Product Description 23
Table 19: Amerimmune LLC Pipeline Products & Ongoing Clinical Trials Overview 25
Table 20: FoxP3 Protein Expression Assay - Product Status 25
Table 21: FoxP3 Protein Expression Assay - Product Description 25
Table 22: Wiscott-Aldrich Protein Expression Assay - Product Status 26
Table 23: Wiscott-Aldrich Protein Expression Assay - Product Description 26
Table 24: Analyticon Biotechnologies AG Pipeline Products & Ongoing Clinical Trials Overview 27
Table 25: Turbitex C 3c Reagent - Product Status 27
Table 26: Turbitex C 3c Reagent - Product Description 28
Table 27: Turbitex C 4 Reagent - Product Status 28
Table 28: Turbitex C 4 Reagent - Product Description 29
Table 29: Turbitex CRP Reagent - Product Status 29
Table 30: Turbitex CRP Reagent - Product Description 30
Table 31: Turbitex CRP Ultra Reagent - Product Status 30
Table 32: Turbitex CRP Ultra Reagent - Product Description 31
Table 33: Beckman Coulter Inc Pipeline Products & Ongoing Clinical Trials Overview 32
Table 34: Access - sFlt-1 Assay - Product Status 33
Table 35: Access - sFlt-1 Assay - Product Description 33
Table 36: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Status 33
Table 37: UniCel DxC 600i Synchron Access Clinical System - sFlt-1 Assay - Product Description 33
Table 38: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Status 34
Table 39: UniCel DxC 680i Synchron Access Clinical System - PlGF Assay - Product Description 34
Table 40: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Status 34
Table 41: UniCel DxC 680i Synchron Access Clinical System - sFlt-1 Assay - Product Description 34
Table 42: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Status 35
Table 43: UniCel DxC 860i Synchron Access Clinical System - PlGF Assay - Product Description 35
Table 44: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Status 35
Table 45: UniCel DxC 860i Synchron Access Clinical System - sFlt-1 Assay - Product Description 36
Table 46: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Status 36
Table 47: UniCel DxC 880i Synchron Access Clinical System - PlGF Assay - Product Description 36
Table 48: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Status 37
Table 49: UniCel DxC 880i Synchron Access Clinical System - sFlt-1 Assay - Product Description 37
Table 50: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Status 37
Table 51: UniCel DxI 600 Access Immunoassay System - PlGF Assay - Product Description 37
Table 52: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Status 38
Table 53: UniCel DxI 600 Access Immunoassay System - sFlt-1 Assay - Product Description 38
Table 54: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Status 38
Table 55: UniCel DxI 660i Synchron Access Clinical System - sFlt-1 Assay - Product Description 38
Table 56: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Status 39
Table 57: UniCel DxI 800 Access Immunoassay System - PlGF Assay - Product Description 39
Table 58: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Status 39
Table 59: UniCel DxI 800 Access Immunoassay System - sFlt-1 Assay - Product Description 40
Table 60: UniCel DxI 860i Synchron Access Clinical System - PlGF Assay - Product Status 40

List of Figures
Figure 1: Specific Proteins - Pipeline Products by Stage of Development 10
Figure 2: Specific Proteins - Pipeline Products by Territory 11
Figure 3: Specific Proteins - Pipeline Products by Regulatory Path 12
Figure 4: Specific Proteins - Pipeline Products by Estimated Approval Date 13

Filed in: Pharmaceutical, Pharmaceuticals and Healthcare

Publisher : GlobalData

Name:
Email:
Phone:
Subject:
Comments:

More Reports

Title	Price	Buy Now
Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027 “The ambulatory EHR market is projected to grow at a CAGR of 6.1% between 2022 and 2027.” The global ambulatory EHR market is projected to reach USD 5.7 billion in 2022 to USD 7.7 billion by 2027, at a CAGR of 6.1%during the forecast period. Growth in this market is driven by the opportunities provided by the market such as increasing demand for cloud-based ambulatory EHR market, and shift towards patient-centric healthcare delivery. However, the interoperability issues & data security concerns are some of the challenges that are expected to limit the growth of the market to a certain extent during the forecast period. “Cloud-based was the fastest-growing segment in the delivery mode of ambulatory EHR market in 2021” Cloud-based segment is projected to growth at the hi......	$4950
Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027 “The pharmaceutical excipients market growth can be attributed to factors such as the rising pharmaceuticals market, advancements in functional excipients, and the growing generics market. The rapidly growing biopharmaceuticals sector will also influence market growth..” The pharmaceutical excipients market is projected to reach USD 11.5 Billion by 2027 from USD 8.6 Billion in 2022, at a CAGR of 5.9% during the forecast period.The growth can be attributed to the expanding pharmaceutical industry which has fueled the drug production thereby increasing consumption rate for excipients. Additionally, factors like functional excipients development and upsurge in generics market is also likely to propel market growth. “The fillers & diluents functionality accounted for the larges......	$
Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027 “Digital Pharmacy market to register a CAGR of 17.0% during the forecasts period The digital pharmacy market is expected to reach USD 211.9 billion by 2027 from USD 96.5 billion in 2022, at a CAGR of 17.0% during the forecast period. The growth of this market is driven by the growing consumer preference toward buying online medicines during and post COVID-19 pandemic, consolidation in the market and partnerships, and increasing geriatric population. However, patients relying on pharmacists for clinical support and increasing number of illegal pharmacies are expected to restrain the growth of this market during the forecast period. “Over-the-counter (OTC) products segment is estimated to grow at the highest rate during the forecast period” On the basis ofdrug type, t......	$4950
Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027 The pharmacy automation market is expected to grow at a CAGR of 7.9% in the forecast period. The pharmacy automation market is projected to reach USD 8.2 billion by 2027 from USD 5.6 billion in 2022, at a CAGR of 7.9% during the forecast period. The growth in this market is attributed to the growing need to minimize medication errors, rapid decentralization of pharmacies, and growing focus on automation to reduce labor costs. However, the stringent regulations that delay product launches can inhibit the growth of this market. Based on product, the automated medication dispensing and storage systems segment holds the largest market share in 2021 Based on products, the pharmacy automation market is segmented into automated medication dispensing and storage systems, automated packagi......	$4950
Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027 The topical drug delivery market is expected to grow at a CAGR of 8.9% in the forecast period. The global topical drug delivery market is projected to reach USD 317.8 billion by 2027 from USD 207.4 billion in 2022, at a CAGR of 8.9%. The growth of this market can largely be attributed to the high prevalence of topical prescription therapy for dry eye diseases, growing focus of pharmaceutical companies on the R&D of smart transdermal drug delivery systems, increase in prevalence of central nervous disorders, rising preference for non-invasive drug delivery methods. “The semi-solid formulation segment accounted for the largest share of the topical drug delivery market, based on product in 2021.” Based on products, the topical drug delivery the market is segmented into ......	$4950
Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026 “Increasing incidence and prevalence of neurological disorders is a key factors driving growth in the cognition and memory enhancement market’’ The global cognition and memory enhancement market is projected to reach USD 38.9 billion by 2026 from USD 23.4 billion in 2021, at a CAGR of 10.7% during the forecast period. Elevating prevalence of neurological disorders, such as dementia, epilepsy, Parkinson’s disease, Huntington’s disease, headache disorders, multiple sclerosis, neuroinfections, stroke, and cerebral palsy, have increased significantly over the years. “By product & service segment, the cognition & memory-enhancing drugs segment has registered fastest growth rate during the forecast period” Based on product & service, the cognition and memory en......	$4950
High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027 The HPAPI market is projected to reach USD 39.6 Billion by 2027 from USD 24.5 billion in 2022, at a CAGR of 10.1% from 2022 to 2027. The market is driven by increasing demand for oncology drugs, growing demand for antibody-drug conjugates and others. “The innovative HPAPIs segment is expected to account for the largest share of the market in 2021” Based on type, the HPAPI market is segmented into innovative and generic. The innovative segment is expected to account for the largest share of the HPAPI market in 2021. The large share can be attributed to the increased R&D investments. “The Synthetic APIs segment to account for the largest share of the market in 2021” Based on type of synthesis, the market is segmented into synthetic and biotech HPAPIs. The synthetic AP......	$4950
Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027 “Increased risk of communicable diseases, Rising prevalence of bleeding disorders in global population, Use of Immunoglobulin’s for a range of neurological conditions, including multiple sclerosis, neuropathic pain, and chronic fatigue syndrome is expected to drive the overall growth of the plasma fractionation market.” The global plasma fractionation market size is projected to reach USD 36.7 billion by 2027 from USD 26.5 billion in 2022, at a CAGR of 6.7% during the forecast period. Market growth is driven mainly by factors such as rapid growth of geriatric population, growing prevalence of respiratory disorders such as alpha-1-antitrypsin deficiency (AATD) and emphysema, and use of plasma fractionation products as first-line therapies for a number of bleeding, hematological, an......	$4950
Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027 “Patient engagement solutions market to register a CAGR of 10.0% from 2022 to 2027” The patient engagement solutions market is projected to reach USD 27.9 billion by 2027 from USD 17.3 billion in 2022, at a CAGR of 10.0% during the forecast period. The growth of this market is driven by the adoption and changes in government regulations to promote patient-centric care and involve patients throughout the care journey, high demand for patient engagement solutions, and the growing utilization of m- health apps. However, interoperability issues for patient engagement solutions and a dreadth of skilled IT professionals in the healthcare industry are expected to restrain the growth of this market during the forecast period. “Services segment is expected to grow at the highest rate......	$4950
Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027 The global Healthcare cloud computing market is projected to reach USD 89.4 billion by 2027 from USD 39.4 billion in 2022, at a CAGR of 17.8%. The factors driving the market are adoption of technologies like telehealth, EHR, big data analytics, IoT, cloud computing, m health, wearlable devices, etc. “The healthcare provider solution was the largest segment in the healthcare cloud computing market in 2021.” The healthcare provider segment accounted for the larger share of 79.2% of the healthcare cloud computing market in 2021. The growing adoption of various health IT solutions such as EHR, e-prescribing, telehealth, mHealth, and others due to COVID-19 is one of the key factors contributing to the growth of this segment. “Among end users, the healthcare providers segment ac......	$4950

Specific Proteins - Medical Devices Pipeline Assessment, 2019

Benefits of Sandler Research

User License for Reports

Reach Us

Contact Us

Knowledge Store

Email Subscription

our Feed Reader

Ambulatory EHR Market by Delivery Mode (Cloud-based, On-premise), Application (e-Prescribing, PHM, Health Analytics, Practice, Patient & Referral Management), Practice Size (Large, Small-to-Medium, Solo), End User (Independent) – Global Forecast to 2027

Pharmaceutical Excipients Market by Product (Organic Chemicals (Carbohydrates), Inorganic Chemicals (Calcium Phosphate)), Functionality (Fillers, Binders, Lubricants, Preservatives), Formulation (Tablets, Capsules, Parenteral) – Global Forecast to 2027

Digital Pharmacy Market by Drug (Rx, OTC), Product (Medicine, Personal Care, Vitamins & Supplements, Diabetes, CVD, Oncology), Platform (Apps, Websites), Business Model (Captive, Franchise, Aggregator), Geographic (Urban, Rural) – Global Forecasts to 2027

Pharmacy Automation Market by Product (Automated Medication Dispensing & Storage Systems, Table-Top Counters, Retrieval Systems, Medication Compounding), End User (Inpatient, Outpatient (Fast-Track Clinics), Retail Pharmacies) – Global Forecast to 2027

Topical Drug Delivery Market by Type (Semi-solids (Creams, Gels, Lotions), Solids(Suppositories), Liquids(Solutions), Transdermal products), Route(Dermal, Ophthalmic), Facility of Use (Homecare setting, Hospitals, Burn Centres) – Global Forecast to 2027

Cognition and Memory Enhancement Market by Product & Service (Cognition & Memory-enhancing Drugs, Brain-boosting Nutraceuticals, Cognitive Assessment & Training Solutions), Region (North America, Europe, Asia Pacific, ROW) – Global Forecast to 2026

High Potency APIs/HPAPI Market by Type (Innovative, Generic), Type of Synthesis (Synthetic, Biotech, Biosimilars, mAbs, Vaccines), Manufacturers (Captive, Merchant), Application (Oncology, Hormonal Imbalance, Glaucoma) Region – Global forecast to 2027

Plasma Fractionation Market by Product (Immunoglobulins, Albumin, Protease Inhibitors, von Willebrand Factor, PCC), Application (Neurology, Immunology, Hematology, Rheumatology), End User (Clinical Research, Hospitals & Clinics) – Global Forecast to 2027

Patient Engagement Solutions Market by Component (Software, Services), Delivery (On-Premise, Cloud), Therapy Area (CVD, Diabetes, Obesity, Fitness), Functionality (E-prescribing, Virtual care), End User (Provider, Payer, Patients) – Global Forecast to 2027

Healthcare Cloud Computing Market by Product (EMR/EHR, VNA, RIS, LIS, PIS), Deployment (Private Cloud, Hybrid Cloud, Public Cloud), Component (Software, Services), Pricing (Spot Pricing), Service (SaaS, IaaS, PaaS), End User – Global Forecasts to 2027